{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T19:02:17Z","timestamp":1775502137105,"version":"3.50.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Takotsubo syndrome (TTS) is an acute stress-induced cardiomyopathy that mimics acute coronary syndrome and is recognized in patients with malignancy. Outcomes analyses and contemporary cardio-oncology reviews further emphasize malignancy as a clinically meaningful modifier of TTS risk, phenotype, and prognosis. Cancer patients represent a uniquely vulnerable population due to the combined effects of emotional stress, systemic inflammation, autonomic imbalance, and exposure to potentially cardiotoxic therapies. Targeted anticancer agents that perturb vascular homeostasis (eg, vascular endothelial growth factor-pathway inhibition) also contribute to endothelial dysfunction, hypertension, thromboinflammation, and myocardial stress\u2014mechanisms that plausibly lower the threshold for stress cardiomyopathy in susceptible patients. Evidence suggests that TTS in the oncology setting is associated with higher complication rates, increased mortality, and complex diagnostic and management challenges compared with noncancer populations. Large-scale database studies and propensity-matched real-world analyses reinforce the need for cancer-specific risk stratification and tailored cardiovascular management pathways. Moreover, cancer-associated TTS often occurs at critical junctures, including at diagnosis, during active treatment, or in the perioperative period, and may reflect underlying disease severity or physiological frailty. This review explores the epidemiology, pathophysiological mechanisms, and clinical presentation of TTS in patients with cancer, with particular emphasis on neurohormonal activation, inflammatory pathways, endothelial dysfunction, and treatment-related triggers.<\/jats:p>","DOI":"10.1097\/crd.0000000000001269","type":"journal-article","created":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T18:00:21Z","timestamp":1775498421000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Cancer-Associated Takotsubo Syndrome: An Emerging Intersection of Cardio-Oncology"],"prefix":"10.1097","author":[{"given":"Jatin","family":"Thukral","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, New York Medical College\/Landmark Medical Center, Woonsocket, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pyush","family":"Moudgil","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gian Sagar Medical College and Hospital, Ramnagar, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ninaad","family":"Sindhwani","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gian Sagar Medical College and Hospital, Ramnagar, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanshika","family":"Garg","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gian Sagar Medical College and Hospital, Ramnagar, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diksha","family":"Grover","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gian Sagar Medical College and Hospital, Ramnagar, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harnoor","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Medicine, Gian Sagar Medical College and Hospital, Ramnagar, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riya Kaushal","family":"Shah","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, New York Medical College\/Landmark Medical Center, Woonsocket, RI"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Harbir","family":"Kaur","sequence":"additional","affiliation":[{"name":"Department of Medicine, Internal Medicine, Hamilton Medical Center, Dalton, GA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikhil","family":"Thukral","sequence":"additional","affiliation":[{"name":"Department of Occupational Therapy, Pt. Deendayal Upadhyaya National Institute for Persons With Physical Disabilities, New Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilbert S.","family":"Aronow","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College and Westchester Medical Center, Valhalla, NY."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2026,4,6]]},"reference":[{"key":"R1-20260406","doi-asserted-by":"crossref","first-page":"197","DOI":"10.3390\/jcm15010197","article-title":"Takotsubo syndrome in 2025: evolving concepts in pathophysiology, diagnosis, and long-term management.","volume":"15","author":"McKenzie","year":"2025","journal-title":"J Clin Med"},{"key":"R2-20260406","doi-asserted-by":"crossref","first-page":"2718","DOI":"10.3390\/biomedicines13112718","article-title":"Takotsubo syndrome and cancer: pathophysiological links and clinical perspectives.","volume":"13","author":"Correra","year":"2025","journal-title":"Biomedicines"},{"key":"R3-20260406","doi-asserted-by":"crossref","first-page":"1301383","DOI":"10.3389\/fcvm.2023.1301383","article-title":"A contemporary update on cancer and takotsubo syndrome.","volume":"10","author":"Tini","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"R4-20260406","doi-asserted-by":"crossref","first-page":"1244808","DOI":"10.3389\/fcvm.2023.1244808","article-title":"Clinical outcomes of takotsubo syndrome in patients with cancer: a systematic review and meta-analysis.","volume":"10","author":"Osawa","year":"2023","journal-title":"Front Cardiovasc Med"},{"key":"R5-20260406","first-page":"100723","article-title":"Cancer therapy-associated Takotsubo cardiomyopathy: a narrative review of mechanisms, drug associations, and clinical implications.","volume":"63","author":"Simeon","year":"2026","journal-title":"Am Heart J Plus"},{"key":"R6-20260406","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.hrtlng.2012.09.004","article-title":"Chronobiological variation in the occurrence of Tako-tsubo cardiomyopathy: experiences of two tertiary cardiovascular centers.","volume":"42","author":"Song","year":"2013","journal-title":"Heart Lung"},{"key":"R7-20260406","first-page":"7","article-title":"Takotsubo cardiomyopathy in cancer patients.","volume":"5","author":"Desai","year":"2019","journal-title":"Cardiooncology"},{"key":"R8-20260406","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.3390\/ijms23041951","article-title":"Takotsubo syndrome: translational implications and pathomechanisms.","volume":"23","author":"Fan","year":"2022","journal-title":"Int J Mol Sci"},{"key":"R9-20260406","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3892\/ijmm.2025.5615","article-title":"Takotsubo syndrome: unraveling the mystery behind its triggers (Review).","volume":"56","author":"Fan","year":"2025","journal-title":"Int J Mol Med"},{"key":"R10-20260406","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1007\/s11886-025-02342-4","article-title":"The role of inflammation in takotsubo syndrome: from pathogenic pathways to imaging insights and therapeutic perspectives.","volume":"28","author":"Madaudo","year":"2026","journal-title":"Curr Cardiol Rep"},{"key":"R11-20260406","doi-asserted-by":"crossref","first-page":"995","DOI":"10.3390\/biom13060995","article-title":"Blood biomarkers in takotsubo syndrome point to an emerging role for inflammaging in endothelial pathophysiology.","volume":"13","author":"Nagai","year":"2023","journal-title":"Biomolecules"},{"key":"R12-20260406","article-title":"VEGF inhibitors in hematologic cancers and hypertension\/cardiac effects [published online ahead of print February 24, 2026].","author":"Thukral","journal-title":"Cardiol Rev"},{"key":"R13-20260406","article-title":"Understanding arrhythmia-induced cardiomyopathy: symptoms and treatments [published online ahead of print July 18, 2024].","author":"Desai","journal-title":"Cardiol Rev"},{"key":"R14-20260406","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s43044-025-00628-0","article-title":"Cardiomyopathies and a brief insight into DOX-induced cardiomyopathy.","volume":"77","author":"Tanwar","year":"2025","journal-title":"Egypt Heart J"},{"key":"R15-20260406","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.cpt.2024.04.004","article-title":"Cardiotoxicity in platinum-based chemotherapy: mechanisms, manifestations, and management.","volume":"3","author":"Rachma","year":"2025","journal-title":"Cancer Pathog Ther"},{"key":"R16-20260406","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.jcmg.2017.11.036","article-title":"Takotsubo-like syndrome in cancer patients treated with immune checkpoint inhibitors.","volume":"11","author":"Ederhy","year":"2018","journal-title":"JACC Cardiovasc Imaging"},{"key":"R17-20260406","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1007\/s12350-020-02444-2","article-title":"Immune checkpoint inhibitor myocarditis mimicking Takotsubo cardiomyopathy on MPI.","volume":"29","author":"Norikane","year":"2022","journal-title":"J Nucl Cardiol"},{"key":"R18-20260406","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1111\/imj.16493","article-title":"Clinical perspectives: Takotsubo cardiomyopathy.","volume":"54","author":"Ravindran","year":"2024","journal-title":"Intern Med J"},{"key":"R19-20260406","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nrcardio.2015.116","article-title":"Important role of myocardial tissue characterization by cardiac MRI in diagnosing Takotsubo syndrome.","volume":"12","author":"Garg","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"R20-20260406","doi-asserted-by":"crossref","first-page":"e939020","DOI":"10.12659\/MSM.939020","article-title":"Epidemiology, pathophysiology, diagnosis, and principles of management of Takotsubo cardiomyopathy: a review.","volume":"29","author":"Matta","year":"2023","journal-title":"Med Sci Monit"},{"key":"R21-20260406","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.amjcard.2026.01.006","article-title":"Effectiveness and safety of apixaban versus warfarin in atrial fibrillation patients with malignancy: a propensity-matched analysis.","volume":"264","author":"Agrawal","year":"2026","journal-title":"Am J Cardiol"},{"key":"R22-20260406","article-title":"Impact of beta blockers on long-term mortality in takotsubo syndrome: a real-world analysis of the TriNetX Global Collaborative Network Database [published online ahead of print November 18, 2025].","author":"Jain","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"R23-20260406","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1161\/CIRCRESAHA.115.303633","article-title":"Cardio-oncology: an update on cardiotoxicity of cancer-related treatment.","volume":"118","author":"Lenneman","year":"2016","journal-title":"Circ Res"},{"key":"R24-20260406","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1002\/ejhf.1920","article-title":"Baseline cardiovascular risk assessment in cancer patients scheduled to receive cardiotoxic cancer therapies: a position statement and new risk assessment tools from the Cardio-Oncology Study Group of the Heart Failure Association of the European Society of Cardiology in collaboration with the International Cardio-Oncology Society.","volume":"22","author":"Lyon","year":"2020","journal-title":"Eur J Heart Fail"},{"key":"R25-20260406","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/eurheartj\/ehy076","article-title":"International Expert Consensus Document on Takotsubo Syndrome (Part I): clinical characteristics, diagnostic criteria, and pathophysiology.","volume":"39","author":"Ghadri","year":"2018","journal-title":"Eur Heart J"},{"key":"R26-20260406","doi-asserted-by":"crossref","first-page":"1981","DOI":"10.1161\/CIRCULATIONAHA.114.013777","article-title":"Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy.","volume":"131","author":"Cardinale","year":"2015","journal-title":"Circulation"},{"key":"R27-20260406","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1016\/j.amjcard.2011.01.006","article-title":"Early detection and prediction of cardiotoxicity in chemotherapy-treated patients.","volume":"107","author":"Sawaya","year":"2011","journal-title":"Am J Cardiol"},{"key":"R28-20260406","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"key":"R29-20260406","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/j.jacc.2006.07.052","article-title":"Protective effects of carvedilol against anthracycline-induced cardiomyopathy.","volume":"48","author":"Kalay","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"R30-20260406","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1016\/j.jacc.2013.02.072","article-title":"Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of malignant hemopathies).","volume":"61","author":"Bosch","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"R31-20260406","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis.","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"R32-20260406","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1111\/j.1538-7836.2011.04215.x","article-title":"Rates of venous thromboembolism in multiple myeloma patients undergoing immunomodulatory therapy with thalidomide or lenalidomide: a systematic review and meta-analysis.","volume":"9","author":"Carrier","year":"2011","journal-title":"J Thromb Haemost"},{"key":"R33-20260406","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/j.thromres.2015.07.011","article-title":"Efficacy and safety of anticoagulant agents in patients with venous thromboembolism and cancer: a network meta-analysis.","volume":"136","author":"Vedovati","year":"2015","journal-title":"Thromb Res"},{"key":"R34-20260406","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1056\/NEJMoa025313","article-title":"Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.","volume":"349","author":"Lee","year":"2003","journal-title":"N Engl J Med"},{"key":"R35-20260406","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1056\/NEJMra1100265","article-title":"Cardiovascular toxic effects of targeted cancer therapies.","volume":"375","author":"Moslehi","year":"2016","journal-title":"N Engl J Med"},{"key":"R36-20260406","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1111\/jth.14613","article-title":"Direct oral anticoagulant for the prevention of thrombosis in ambulatory patients with cancer: a systematic review and meta-analysis.","volume":"17","author":"Li","year":"2019","journal-title":"J Thromb Haemost"},{"key":"R37-20260406","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/rth2.12111","article-title":"Management of anticoagulation for cancer-associated thrombosis in patients with thrombocytopenia: a systematic review.","volume":"2","author":"Samuelson Bannow","year":"2018","journal-title":"Res Pract Thromb Haemost"},{"key":"R38-20260406","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.amjcard.2018.11.006","article-title":"Frequency of Takotsubo Cardiomyopathy in adult patients receiving chemotherapy (from a 5-Year Nationwide Inpatient Study).","volume":"123","author":"Desai","year":"2019","journal-title":"Am J Cardiol"},{"key":"R39-20260406","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1038\/nrcardio.2015.39","article-title":"Epidemiology and pathophysiology of Takotsubo syndrome.","volume":"12","author":"Akashi","year":"2015","journal-title":"Nat Rev Cardiol"},{"key":"R40-20260406","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.jacc.2018.06.016","article-title":"Long-term prognosis of patients with Takotsubo syndrome.","volume":"72","author":"Ghadri","year":"2018","journal-title":"J Am Coll Cardiol"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001269","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,6]],"date-time":"2026-04-06T18:00:26Z","timestamp":1775498426000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001269"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,6]]},"references-count":40,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001269","relation":{},"ISSN":["1061-5377","1538-4683"],"issn-type":[{"value":"1061-5377","type":"print"},{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,6]]}}}